[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monoclonal-gammopathy-of-undetermined-significance-mgus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monoclonal-gammopathy-of-undetermined-significance-mgus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,78,115,149,178,189,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053511","chaamp-charlotte-advocate-mgus-project-internal-pilot-study-100053511",false,"NCT06644625","CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study","SCREENING Inclusion Criteria:\n\n* Age 30 years or older at the time of consent\n* Either:\n\n  1. Self-identify as Black and\u002For African American OR\n  2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia\n* Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately\n* Reside in Charlotte, NC, or the surrounding area, based on self-report\n\nSCREENING Exclusion Criteria:\n\n* Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.\n\nLONGITUDINAL Inclusion Criteria:\n\n* Test positive for monoclonal gammopathy during screening portion of the study\n* Consent to the longitudinal portion of the study\n\nLONGITUDINAL Exclusion Criteria:\n\n* The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.",true,"ALL","30 Years",{"count":19,"type":20},1665,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.",[24,25,26,27,28],"Multiple Myeloma","Multiple Myeloma Progression","Monoclonal Gammopathy of Undetermined Significance (MGUS)","Smoldering Multiple Myeloma (SMM)","Plasma Cell Disorders",[30,31,32],"multiple myeloma","hematology","plasma cell disorders","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2025-03-01",{"date":41,"type":20},"2035-01",{"name":43,"class":44},"Wake Forest University Health Sciences","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100526882","phase-2-a-proof-of-concept-study-to-learn-whether-linvoseltamab-can-eliminate-abnormal-plasma-cells-that-may-lead-to-multiple-myeloma-in-adult-patients-with-high-risk-monoclonal-gammopathy-of-undetermined-significance-or-non-high-risk-smoldering-multiple-myeloma-100526882","NCT06140524","A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","LINKER-MGUS1","Key Inclusion Criteria:\n\n1. HR-MGUS or NHR-SMM as defined in the protocol\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n3. Adequate hematologic and hepatic function, as described in the protocol\n4. Estimated glomerular filtration rate (GFR) ≥30 mL\u002Fmin\u002F1.73 m\\^2 by the Modification of Diet in Renal Disease (MDRD) equation\n\nKey Exclusion Criteria:\n\n1. High-risk SMM, as defined in the protocol\n2. Evidence of any of myeloma-defining events, as described in the protocol\n3. Diagnosis of systemic light-chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), solitary plasmacytoma, or symptomatic MM\n4. Clinically significant cardiac or vascular disease within 3 months of study enrollment, as described in the protocol\n5. Any infection requiring hospitalization or treatment with intravenous (IV) anti-infectives within 28 days of the first dose of linvoseltamab\n6. Uncontrolled Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection; or other uncontrolled infection or unexplained signs of infection, as described in the protocol\n\nNOTE: Other protocol defined inclusion\u002Fexclusion criteria apply","18 Years",{"count":56,"type":20},116,"INTERVENTIONAL",[59],"PHASE2","This study is researching an investigational drug called linvoseltamab (\"study drug\") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance (HR-MGUS) and Non-High-Risk Smoldering Multiple Myeloma (NHR-SMM).\n\nThe primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of HR-MGUS and NHR-SMM.\n\nThe study is looking at several other research questions, including:\n\n* How many participants treated with linvoseltamab have improvement of their HR-MGUS or NHR-SMM?\n* What side effects may happen from taking the study drug?\n* How much study drug is in the blood at different times?\n* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).",[26,27],[63,64,65,66,32],"linvoseltamab","monoclonal immunoglobulin (M-protein)","cancer interception","immunotherapy","2026-06-12",{"date":69,"type":37},"2026-06-15",{"date":71,"type":37},"2024-09-16",{"date":73,"type":20},"2032-05-18",{"name":75,"class":76},"Regeneron Pharmaceuticals","INDUSTRY",39,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":57,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":45},"100639454","early-detection-of-amyloidosis-in-monoclonal-gammopathy-using-nuclear-medicine-imaging-100639454","NCT07624760","Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging","Early Detection of Light-Chain Amyloidosis in Monoclonal Gammopathy Using 18F-Florbetaben PET\u002FMR: a Prospective, Single-Center, Observational Study","MGUS-PET","Inclusion Criteria:\n\n* Participation in the COSMO-AL study\n* Available biopsy test result\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating women",{"count":87,"type":20},50,[89],"NA","The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET\u002FMR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET\u002FMR identify systemic amyloid deposits across clinically and histologically defined patient groups?\n\nParticipants will:\n\n* Be screened for eligibility and asked to sign an informed consent form\n* Have their vital signs measured\n* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET\u002FMR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET\u002FCT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner\n* Be monitored during and after the scan for any side effects or adverse events\n* Complete study participation at the end of the imaging session (single visit, no follow-up required)",[92,26,24,93,94],"Monoclonal Gammopathy","AL Amyloidosis","Systemic Amyloidosis",[96,97,98,99,100,101,102,103,104],"MGUS","MGCS","Amyloid PET","PET\u002FMRI","Florbetaben","Early detection","Systemic amyloidosis","Monoclonal gammopathy","AL amyloidosis","NOT_YET_RECRUITING","2026-05-28",{"date":108,"type":37},"2026-06-03",{"date":110,"type":20},"2026-10",{"date":112,"type":20},"2028-05",{"name":114,"class":44},"University of Zurich",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":124,"conditions":125,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100229822","study-of-mgus-smoldering-myeloma-early-mds-and-cll-to-assess-molecular-events-of-progression-and-clinical-outcome-100229822","NCT02269592","Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome","Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome","Inclusion Criteria:\n\n* Patients with Known or Suspected Precursor Hematological Cancer\n* Including the following subgroups of diseases:\n\n  * Early MDS, including pathologically-confirmed MDS (IPSS Low\u002FInt-1; IPSS-R Very Low\u002FLow) and idiopathic cytopenias of undetermined significance (ICUS);\n  * Asymptomatic Multiple Myeloma and Waldenstrom Macroglobulinemia such as monoclonal gammopathy of undermined significance (MGUS) or Smoldering Multiple Myeloma (SMM or SWM);\n  * Monoclonal B cell lymphocytosis (MBL);\n  * Early stage asymptomatic low-grade lymphomas; or\n  * Other precursor conditions or clonal genetic abnormalities of the blood\u002Fbone marrow that do not meet criteria for symptomatic hematological malignancy, or patients exposed to prior chemotherapies (e. g., alkylating agents, platinum derivatives, taxanes, topo-2 inhibitors, anti-metabolites, systemic radioisotopes).\n* Patients must be at least 18 years of age to participate in this research.\n* Inclusion of Women and Minorities -- In accordance with NIH guidelines, women and members of minority groups and their subpopulations will be included in this protocol.\n\nExclusion Criteria:\n\n* Patients with Known or Suspected Precursor Hematological Cancer are NOT EXCLUDED\n* Evidence of symptomatic or active hematological malignancy. Patients enrolled on clinical trials for precursor diseases are NOT excluded from this study.",{"count":123,"type":20},10000,"Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered.\n\nSome of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called \"molecular\" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study.\n\nThis research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA",[26,126,127,128,129,130,131,132],"Myelodysplastic Syndromes","Hematological Malignancies","B-cell Malignancy, Low-grade","Myelodysplastic Syndrome With Low-grade Lesions","IgG Monoclonal Gammopathy of Uncertain Significance","Smoldering Multiple Myeloma","Waldenstrom Macroglobulinemia",[96,134,135,132,136,137,131,138],"Smoldering Myeloma","Acute Myeloid Leukemia","Monoclonal Gammopathy of Undermined Significance","Monoclonal B cell lymphocytosis","Myelodysplastic syndromes","2026-05-04",{"date":141,"type":37},"2026-05-07",{"date":143,"type":37},"2014-08",{"date":145,"type":20},"2030-09",{"name":147,"class":44},"Dana-Farber Cancer Institute",7,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":15,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":177},"100609418","integrative-multi-omics-analysis-to-predict-monoclonal-gammopathies-clinical-evolution-100609418","NCT07214324","Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution","PNRR-2022-1237","Inclusion Criteria:\n\n* Age \\>18 years\n* Male or female patients\n* Histologically confirmed diagnosis of MGUS, SMM, or MM according to ESMO 2021 guidelines\n* Willing and able to provide written informed consent\n\nHEALTHY VOLUNTEERS (HV)\n\n* Age \\>60 years\n* Diagnosis of osteoarthritis (OA)\n* Scheduled for hospitalization for surgical treatment of OA (endoprosthesis or arthroplasty)\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Patients:\n\n  * Active current infection\n  * Autoimmune disease\n  * Women of childbearing potential unable to exclude pregnancy\n  * Use of high-dose corticosteroids within the past 7 days, potentially affecting immunome composition\n\nHealthy Volunteers:\n\n* Prior joint surgery or severe joint deformity\n* Recent trauma, osteonecrosis, or OA caused by prior\u002Fcurrent joint infection\n* Metabolic disorders\n* Previous or current cancer diagnosis\n* Autoimmune diseases (e.g., rheumatoid arthritis)",{"count":157,"type":20},60,"This prospective, multicenter, observational study aims to identify molecular and immunological markers associated with disease progression in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). By integrating genomic, transcriptomic, immunophenotypic, and oral microbiome analyses, the study seeks to characterize the biological mechanisms underlying the transition to symptomatic multiple myeloma (MM). The study also includes in vitro modeling to investigate bone damage and immune dysfunction. Healthy volunteers (HV) undergoing joint replacement surgery for osteoarthritis will serve as controls. The ultimate goal is to improve early risk stratification and support future preventive strategies through a multi-omics approach. There is a pressing need for new strategies to identify high-risk individuals based on biological rather than purely clinical parameters. This study proposes an integrative, multi-omics approach to investigate the transition from MGUS\u002FSMM to MM. By analyzing the immunome and oral microbiome alongside molecular profiling, the goal is to identify reliable biomarkers of progression. The resulting insights could be enable more accurate risk stratification and guide the design of future preventive clinical trials aimed at delaying or halting disease evolution.",[26,27,160],"Multiple Myeloma (MM)",[162,163,164,165,166],"plasma cells","multi-omics","biomarkers","bone marrow microenvironment","microbiome","2026-04-22",{"date":169,"type":37},"2026-04-23",{"date":171,"type":37},"2025-03-17",{"date":173,"type":20},"2026-12-31",{"name":175,"class":176},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",4,{"id":179,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":181,"keywords":182,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":188,"locationsCount":45},"100565626",{"count":19,"type":20},[24,25,26,27,28],[30,31,32],"2026-01-15",{"date":185,"type":37},"2026-01-20",{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":15,"sex":16,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":45},"100569157","characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy-100569157","NCT06690593","Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy","Gut Microbiota Profiling in Patients With Monoclonal Gammopathy: Implications for Disease Pathogenesis and Progression","(I) Inclusion Criteria:\n\n1. Age 45 years or older;\n2. Negative screening for monoclonal protein by MALDI-TOF MS;\n3. No significant diseases found upon medical examination, and confirmed not to have any diseases related to this study;\n4. Sufficient whole blood, plasma, serum, and stool samples available, and relevant case data can be provided.\n\n(II) Exclusion Criteria:\n\n1. History of intestinal tumors, irritable bowel syndrome, or inflammatory bowel disease, or diagnosed during hospitalization;\n2. Antibiotic treatment received in the past month; Presence of severe systemic diseases, including malignant tumors;\n3. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice, or other unqualified sample conditions.","45 Years",{"count":198,"type":20},2990,"This is an observational case-control study, aiming to systematically analyze the gut microbiome characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS). The study will collect blood and stool samples from MGUS patients, non-MGUS patients (with similar diseases), and healthy controls, and perform multi-omics detection including microbiomics, peptidomics, and biochemical immunology. It will comprehensively analyze the abnormal features of the gut microbiome in MGUS patients, which may help provide new biomarkers and potential mechanisms for the diagnosis, prognosis evaluation, and treatment strategies of MGUS.",[26,201,24,202],"Intestinal Flora","M-Protein","2024-12-26",{"date":205,"type":37},"2024-12-27",{"date":203,"type":20},{"date":208,"type":20},"2026-12-30",{"name":210,"class":44},"Zhujiang Hospital",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":45},"100461081","a-cohort-study-of-plasma-cell-disorders-pcds-in-pkufh-100461081","NCT05283993","A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH","Inclusion Criteria:\n\n1. Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)\n2. Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).\n3. Patients are included into this cohort after signing the ICFs.\n\nExclusion Criteria:\n\nSignificant comorbidity may be life-threatening.",{"count":219,"type":20},2000,"The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.",[24,222,223,224,225,226,227,131,228,26,229,230],"Amyloidosis","Cryoglobulinemia","Castleman's Disease","Light Chain Deposition Disease","Heavy Chain Deposition Disease","Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes","Plasma Cell Leukemia","Monoclonal Gammopathy of Renal Significance (MGRS)","Monoclonal Gammopathy of Neurological Significance (MGNS)","2022-04-21",{"date":233,"type":37},"2022-04-25",{"date":235,"type":37},"2021-07-01",{"date":237,"type":20},"2030-12-31",{"name":239,"class":44},"Peking University First Hospital"]